Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
BRISBANE, Calif., April 20, 2018 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the first quarter 2018 after the market closes on Thursday, May 10, 2018. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. Please reference Conference ID: 13679056. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: www.CareDx.com.
A replay of the call will be available beginning May 10, 2018 at 4:30pm PT/7:30pm ET through 4:30pm PT/7:30pm ET on May 24, 2018. To access the replay, dial 1-844-512-2921 or 1-412-317-6671 and reference Conference ID: 13679056. The webcast will also be available on CareDx’s website for one year following the completion of the call.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
CONTACTS:
Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
[email protected]
